Zoetis Inc. $ZTS Shares Purchased by Prudential PLC

Prudential PLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 1.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 168,150 shares of the company’s stock after purchasing an additional 2,886 shares during the quarter. Prudential PLC’s holdings in Zoetis were worth $26,223,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Savvy Advisors Inc. grew its position in Zoetis by 54.0% in the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after acquiring an additional 1,114 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Zoetis by 54.3% in the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after purchasing an additional 152 shares during the last quarter. Canoe Financial LP grew its holdings in shares of Zoetis by 859.0% during the 2nd quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock worth $2,085,000 after purchasing an additional 11,975 shares during the period. Strs Ohio purchased a new position in shares of Zoetis during the 1st quarter worth $22,891,000. Finally, Consolidated Investment Group LLC increased its position in shares of Zoetis by 59.6% during the 2nd quarter. Consolidated Investment Group LLC now owns 26,235 shares of the company’s stock worth $4,091,000 after purchasing an additional 9,800 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $116.96 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $181.85. The firm has a market cap of $51.54 billion, a PE ratio of 20.13, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The company’s 50 day moving average is $138.98 and its two-hundred day moving average is $150.66.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the previous year, the firm posted $1.58 earnings per share. The company’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is 33.67%.

Analyst Ratings Changes

A number of research analysts have commented on ZTS shares. Stifel Nicolaus decreased their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday. UBS Group reduced their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Argus reaffirmed a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, JPMorgan Chase & Co. decreased their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.